Rational Drug Design of G-Quartet DNA as Anti-Cancer Agents

Author(s): N. Jing, W. Sha, Y. Li, W. Xiong, D. J. Tweardy

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 22 , 2005

Become EABM
Become Reviewer


The ability of certain DNA sequences to form G-quartet structures has been exploited recently to develop novel anti-cancer agents including small molecules that promote G-quartet formation within the c-MYC promoter thereby repressing c-MYC transcription and introducing G-quartet-forming oligodeoxynucleotides (GQ-ODN) into cancer cells resulting in p53-dependent cell cycle arrest and inhibition of DNA replication. GQ-ODNs also have been developed as potent inhibitors of signal transducer and activator of transcription (STAT) 3, a critical mediator of oncogenic signaling in many cancers. This review summarizes the rational design of G-quartet forming DNA drugs as Stat3 inhibitors. Topics that are reviewed include the strategy of structure-based drug design, establishment of a structure-activity relationship, development of a novel intracellular delivery system for G-quartet-forming DNA agents and in vivo drug testing to assess the anti-cancer effects of DNA drugs in tumor xenografts. Results to date with GQ-ODN targeting Stat3 are encouraging, and it is hoped that continued pursuit of the methodology outlined here may lead to development of an effective agent for treatment of metastatic cancers, such as prostate and breast, in which Stat3 is constitutively activated.

Keywords: dna drugs, g-quartet oligodeoxynucleotides (gq-odn), signal transducer and activator of transcription (stat) 3, apoptosis, cancer therapy, prostate cancer, breast cancer, drug delivery, drug design

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2005
Page: [2841 - 2854]
Pages: 14
DOI: 10.2174/1381612054546761
Price: $65

Article Metrics

PDF: 7